| Literature DB >> 21303827 |
Abstract
Immunoadsorption (IAS) is used as a rescue therapy in severely ill SLE patients who are refractory to conventional therapies. This extracorporeal method aims at the rapid and extensive removal of pathogenic immunocomplexes (ICs) and (auto-)antibodies (Abs). Although past data have shown short- to mid-term efficacy and biocompatibility of IAS in (renal) SLE, it is still an experimental and rather expensive procedure - and evidence from randomized controlled trials (RCTs) is lacking. Nevertheless, IAS is successfully used in life-threatening situations because of its fast mode of action and its acceptable safety profile.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21303827 DOI: 10.1177/0961203310389487
Source DB: PubMed Journal: Lupus ISSN: 0961-2033 Impact factor: 2.911